

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM616121

<b>SUBMISSION TYPE:</b>		NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>		INTELLECTUAL PROPERTY SECURITY AGREEMENT	
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
MELINTA THERAPEUTICS, LLC		12/22/2020	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Silicon Valley Bank		
<b>Street Address:</b>	3003 Tasman Drive, HF 150		
<b>City:</b>	Santa Clara		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	95054		
<b>Entity Type:</b>	Corporation: CALIFORNIA		
<b>PROPERTY NUMBERS Total: 8</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	90039976	MEBRYSA	
<b>Serial Number:</b>	90039973	BYMRASA	
<b>Serial Number:</b>	90039970	KIMYRSA	
<b>Serial Number:</b>	87935592	ORBACTIV (ORITAVANCIN)	
<b>Serial Number:</b>	87668224	VABOMERE MEROPENEM AND VABORBACTAM FOR I	
<b>Serial Number:</b>	87668177		
<b>Serial Number:</b>	87394992	VABOMERE	
<b>Serial Number:</b>	86120316	ORBACTIV	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2023704750		
<b>Email:</b>	ipteam@cogencyglobal.com		
<b>Correspondent Name:</b>	Jennifer Tindie		
<b>Address Line 1:</b>	1025 Vermont Ave NW, Suite 1130		
<b>Address Line 2:</b>	COGENCY GLOBAL INC.		
<b>Address Line 4:</b>	Washington, D.C. 20005		
<b>ATTORNEY DOCKET NUMBER:</b>	1306975 Therapeutics TM		

OP \$215.00 90039976

<b>NAME OF SUBMITTER:</b>	Sarah Mackin
<b>SIGNATURE:</b>	/Sarah Mackin/
<b>DATE SIGNED:</b>	12/22/2020

**Total Attachments: 27**

source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page1.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page2.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page3.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page4.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page5.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page6.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page7.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page8.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page9.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page10.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page11.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page12.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page13.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page14.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page15.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page16.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page17.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page18.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page19.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page20.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page21.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page22.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page23.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page24.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page25.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page26.tif  
source=Closing Copy - E06.a. Intellectual Property Security Agreement (Melinta) - Melinta#page27.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this “Agreement”) is entered into as of December 22, 2020, by and between SILICON VALLEY BANK, a California corporation (“Bank”) and MELINTA THERAPEUTICS, LLC a Delaware limited liability company (“Grantor”).

### RECITALS

A. Bank has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the “Loans”) in the amounts and manner set forth in that certain Loan and Security Agreement by and among Bank, Grantor, MELINTA SUBSIDIARY CORP., a Delaware corporation, TARGANTA THERAPEUTICS CORPORATION, a Delaware corporation, and REMPEX PHARMACEUTICALS, INC., a Delaware corporation, dated as of the date hereof (as the same may be amended, modified or supplemented from time to time, the “Loan Agreement”; capitalized terms used herein are used as defined in the Loan Agreement). Bank is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in its Copyrights, Trademarks, and Patents (as each term is described below) to secure the obligations of Grantor to Bank.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of Grantor’s obligations to Bank, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

1. Grant of Security Interest. Subject to the terms and conditions of the Loan Agreement, to secure Grantor’s obligations to Bank, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how and operating manuals now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(f) [Reserved];

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, or Trademarks and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, or Patents; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding anything to the contrary herein, the Intellectual Property Collateral shall not include any United States intent-to-use trademark or service mark applications filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, at all times prior to the filing of a "Statement of Use" pursuant to Section 1(d) of the Lanham Act or an "Amendment to Allege Use" pursuant to Section 1(c) of the Lanham Act with respect thereto with the United States Patent and Trademark Office or otherwise.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials of the United States to record and register this Agreement upon request by Bank.

3. Authorization. Grantor hereby authorizes Bank to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a

duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Bank with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.

6. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

MELINTA THERAPEUTICS, LLC

By:   
Christine Ann Miller

Title: President and Chief Executive Officer

BANK:

SILICON VALLEY BANK

By: \_\_\_\_\_

Title: \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

MELINTA THERAPEUTICS, LLC

By: \_\_\_\_\_

Title: \_\_\_\_\_

BANK:

SILICON VALLEY BANK

By: Jan C G

Title: Director

EXHIBIT A

Copyrights

Description

Registration/  
Application  
Number

Registration/  
Application  
Date

None.



EXHIBIT B

Patents

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
METHODS OF TREATING BACTERIAL INFECTIONS	Algeria	200232	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Algeria	200270	30-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Australia	2018345317	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Australia	2018360502	30-Oct-2018		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Austria	18183968.9	8-Aug-2011	3412676	12-Feb-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Austria	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Austria	SZ19/2019	29-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Austria	SZ18/2019	29-Mar-2019		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Belgium	18183968.9	8-Aug-2011	3412676	12-Feb-2020

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Belgium	2019C/515	28-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Belgium	2019C/514	28-Mar-2019		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Belgium	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
Antimicrobial Effervescent Formulation	Bolivia	SP-0129-2015	16-Jun-2015		
METHODS OF TREATING BACTERIAL INFECTIONS	Brazil	BR1120200066583	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Brazil	BR112020008498-0	30-Oct-2018		
COMBINTAION OF VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Bulgaria	2020/0018	10-Jul-2020		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Bulgaria	18183968.9	8-Aug-2011	3412676	12-Feb-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Bulgaria	2020/0019	10-Jul-2020		
METHODS OF TREATING BACTERIAL INFECTIONS	Canada	3078238	1-Oct-2018		

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Canada	3080763	30-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Chile	00892-2020	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Chile	01143-2020	30-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	China (People's Republic)	201880072552.X	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	China (People's Republic)	201880079247.3	30-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Colombia	NC2020/0005419	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Colombia	NC2020/0006299	30-Oct-2018		
Antimicrobial Compositions	Colombia	11-071-900	12-Nov-2009	4851	26-Aug-2013
Antimicrobial Compositions with Effervescent Agents	Colombia	NC2016/0006106	19-Jun-2015	35883	2-Sep-2019
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Czech Republic	18183968.9	8-Aug-2011	3412676	12-Feb-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Czech Republic	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Czech Republic	SPC/CZ2019/632	28-Mar-2019		

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Czech Republic	SPC/CZ2019/633	28-Mar-2019		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Denmark	18183968.9	8-Aug-2011	3412676	12-Feb-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Denmark	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Denmark	15788682.1	30-Apr-2015	3140310	7-Aug-2019
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Denmark	CA201900016	28-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Denmark	CA201900015	28-Mar-2019		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Egypt	649/2020	30-Oct-2018		
Antimicrobial Compositions	Egypt	736/2011	12-Nov-2009		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Estonia	18183968.9	8-Aug-2011	3412676	12-Feb-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Estonia	C20200018	9-Jul-2020		

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Estonia	C20200017	9-Jul-2020		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Estonia	15788682.1	30-Apr-2015	3140310	7-Aug-2019
Apparatus and continuous flow process for production of boronic acid derivative	Europe	18747999.3	31-Jan-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Europe	18735813.0	8-Jan-2018		
Process for Making Quinolone Compounds	Europe	09816565.7	23-Sep-2009	2346855	5-Apr-2017
Patent - Radezolid - Process for Synthesis of Biaryl Oxazolidinones	Europe	04779405.2	28-Jul-2004	1660465	17-Dec-2014
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Europe	18183968.9	8-Aug-2011	3412676	12-Feb-2020
A CRYSTALLINE CYCLIC BORONIC ACID ESTER DERIVATIVE, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	European Patent Convention	20156442.4	8-Aug-2011		
METHODS OF TREATING BACTERIAL INFECTIONS	European Patent Convention	18863923.1	1-Oct-2018		
SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF	European Patent Convention	18874877.6	30-Oct-2018		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Finland	18183968.9	8-Aug-2011	3412676	12-Feb-2020

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Finland	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Finland	C20190015	29-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Finland	C20190016	29-Mar-2019		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	France	18183968.9	8-Aug-2011	3412676	12-Feb-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	France	19C1022	1-Apr-2019	19C1022	14-Feb-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	France	19C1021	1-Apr-2019		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	France	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
Process for Making Quinolone Compounds	France	09816565.7	23-Sep-2009	2346855	5-Apr-2017
Methods of treating infections in overweight and obese patients using antibiotics	GCC	26770	16-Mar-2014		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Germany	18183968.9	8-Aug-2011	3412676	12-Feb-2020

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Germany	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Germany	122019000026.7	28-Mar-2019		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Greece	18183968.9	8-Aug-2011	3412676	12-Feb-2020
Antimicrobial Compositions	Guatemala	A-2011-00119	12-Nov-2009		
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Hungary	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Hungary	S1900017	2-Apr-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Hungary	S1900018	2-Apr-2019		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Iceland	18183968.9	8-Aug-2011	3412676	12-Feb-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Iceland	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Iceland	SPC261	28-Mar-2019		

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Iceland	SPC262	28-Mar-2019		
METHODS OF TREATING BACTERIAL INFECTIONS	India	202037018021	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	India	202037020993	30-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Indonesia	P00202003200	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Indonesia	P00202003809	30-Oct-2018		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Ireland	18183968.9	8-Aug-2011	3412676	12-Feb-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Ireland	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Ireland	15788682.1	30-Apr-2015	3140310	7-Aug-2019
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Ireland	2019/017	28-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Ireland	2019/018	28-Mar-2019		



<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
METHODS OF TREATING BACTERIAL INFECTIONS	Japan	2020-519066	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Japan	2020-543266	30-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Jordan	JO/PCT/2020/75	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Jordan	PCT/JO/2020/101	30-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Korea, Republic of	10-2020-7012784	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Korea, Republic of	10-2020-7015638	30-Oct-2018		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Latvia	18183968.9	8-Aug-2011	3412676	12-Feb-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Latvia	CLV20200026	8-Jul-2020		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Latvia	CLV20200025	8-Jul-2020		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Latvia	15788682.1	30-Apr-2015	3140310	7-Aug-2019
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Lithuania	18183968.9	8-Aug-2011	3412676	12-Feb-2020

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Lithuania	PA2020521	10-Jul-2020		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Lithuania	PA2020519	10-Jul-2020		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Luxembourg	18183968.9	8-Aug-2011	3412676	12-Feb-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Luxembourg	LUC00169	6-Jul-2020		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Luxembourg	LUC00168	6-Jul-2020		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Luxembourg	15788682.1	30-Apr-2015	3140310	7-Aug-2019
METHODS OF TREATING BACTERIAL INFECTIONS	Malaysia	PI2020001141	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Malaysia	PI2020001139	30-Oct-2018		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Malta	18183968.9	8-Aug-2011	3412676	12-Feb-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Malta	156/2020	10-Jul-2020		

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Malta	155/2020	10-Jul-2020		
METHODS OF TREATING BACTERIAL INFECTIONS	Mexico	MX/a/2020/003670	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Mexico	MX/a/2020/004425	30-Oct-2018		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Monaco	18183968.9	8-Aug-2011	3412676	12-Feb-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Netherlands	18183968.9	8-Aug-2011	3412676	12-Feb-2020
METHODS OF TREATING BACTERIAL INFECTIONS	New Zealand	763387	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	New Zealand	764335	30-Oct-2018		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Norway	18183968.9	8-Aug-2011	3412676	12-Feb-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Norway	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Norway	2019013	28-Mar-2019		

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Norway	2019014	28-Mar-2019		
METHODS OF TREATING BACTERIAL INFECTIONS	Philippines	1/2020/550249	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Philippines	1/2020/550544	30-Oct-2018		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Portugal	18183968.9	8-Aug-2011	3412676	12-Feb-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Portugal	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Portugal	15788682.1	30-Apr-2015	3140310	7-Aug-2019
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Portugal	967	28-Mar-2019	967	24-Jun-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Portugal	966	28-Mar-2019	966	17-Jun-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Romania	18183968.9	8-Aug-2011	3412676	12-Feb-2020
METHODS OF TREATING BACTERIAL INFECTIONS	Saudi Arabia	520411705	1-Oct-2018		

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Saudi Arabia	520411905	30-Oct-2018		
METHODS OF TREATING BACTERIAL INFECTIONS	Singapore	11202003009Q	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Singapore	11202003762V	30-Oct-2018		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Sweden	18183968.9	8-Aug-2011	3412676	12-Feb-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Sweden	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	Sweden	1990019-0	28-Mar-2019	1990019-0	11-Jun-2020
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	Sweden	1990017-4	28-Mar-2019	1990017-4	11-Jun-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	Switzerland	18183968.9	8-Aug-2011	3412676	12-Feb-2020
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	Switzerland	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
METHODS OF TREATING BACTERIAL INFECTIONS	Thailand	2001001955	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Thailand	2001002464	30-Oct-2018		

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
METHODS OF TREATING BACTERIAL INFECTIONS	United Arab Emirates	P6000488/2020	1-Oct-2018		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	United Arab Emirates	P6000635/2020	30-Oct-2018		
CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF	United Kingdom	18183968.9	8-Aug-2011	3412676	12-Feb-2020
Apparatus and continuous flow process for production of boronic acid derivatives	United Kingdom	15870720.8	9-Dec-2015	3233869	25-Sep-2019
CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF	United Kingdom	11816882.2	8-Aug-2011	EP2603514	18-Jul-2018
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	United Kingdom	15788682.1	30-Apr-2015	3140310	7-Aug-2019
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF	United Kingdom	SPC/GB19/020	21-Mar-2019		
VABORBACTAM AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE	United Kingdom	SPC/GB19/021	21-Mar-2019		
METHODS OF TREATING BACTERIAL INFECTIONS	United States of America	16/753288	2-Apr-2020		
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	United States of America	16/760369	29-Apr-2020		
ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	15/399,159	05-Jan-2017	10259825	16-Apr-2019




<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	14/917,921	09-Sep-2014	10106543	23-Oct-2018
ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	14/917,920	09-Sep-2014	9937183	10-Apr-2018
ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	14/884,985	16-Oct-2015	9845297	19-Dec-2017
ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	14/681,806	08-Apr-2015	9573962	21-Feb-2017
ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	14/112,027	11-Apr-2012	9221827	29-Dec-2015
ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	13/501,834	15-Oct-2010	9216979	22-Dec-2015
ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	13/501,825	15-Oct-2010	9193731	24-Nov-2015
ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	13/501,836	15-Oct-2010	9023843	05-May-2015
TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	13/918,344	14-Jun-2013	9085600	21-Jul-2015
TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	13/972,732	21-Aug-2013	9006189	14-Apr-2015
HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME	United States of America	15/439,206	22-Feb-2017	10328118	25-Jun-2019
HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME	United States of America	16/437361	11-Jun-2019	20190290723	26-Sep-2019

<u>Description</u>	<u>Country</u>	<u>Application No.</u>	<u>Filing/ Priority Date</u>	<u>Patent No.</u>	<u>Grant Date</u>
METHODS OF INHIBITING AND TREATING BIOFILMS USING GLYCOPEPTIDE ANTIBIOTICS	United States of America	12/936,722	02-Apr-2009	10201587	12-Feb-2019
RIBOSOME STRUCTURE AND PROTEIN SYNTHESIS INHIBITORS	United States of America	13/924,155	21-Jun-2013	8912150	16-Dec-2014
MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	United States of America	13/525,900	18-Jun-2012	8841263	23-Sep-2014
SYNTHESIS OF BORONATE SALTS AND USES THEREOF	Vietnam	1-2020-02894	30-Oct-2018		


















EXHIBIT C



Trademarks

<u>Trademark</u>	<u>Country</u>	<u>Application #</u>	<u>Application Date</u>	<u>Registration #</u>	<u>Registration Date</u>
MEBRYSA	USA	90039976	07/07/2020	N/A	N/A
BYMRASA	USA	90039973	07/07/2020	N/A	N/A
KIMYRSA	USA	90039970	07/07/2020	N/A	N/A
 <b>Orbactiv</b> (oritavancin)	USA	87935592	05/24/2018	N/A	N/A
 <b>VABOMERE</b> meropenem and vaborbactam for injection	USA	87668224	11/01/2017	5681621	02/19/2019
	USA	87668177	11/01/2017	5587889	10/16/2018
VABOMERE	USA	87394992	03/31/2017	5566623	09/18/2018
ORBACTIV	USA	86120316	11/15/2013	4664703	12/30/2014
ORBACTIV	Brazil	907643558	05/05/2014	907643558	04/17/2018
ORBACTIV	Canada	1673540	04/22/2014	TMA1007968	10/31/2018
ORBACTIV	South Africa	201410290	04/22/2014	201410290	04/22/2014

<u>Trademark</u>	<u>Country</u>	<u>Application #</u>	<u>Application Date</u>	<u>Registration #</u>	<u>Registration Date</u>
ORBACTIV (IR 1204701)	Australia	1204701	04/21/2014	1626706	09/18/2014
ORBACTIV (IR 1204701)	China (People's Republic)	1204701	04/21/2014	1204701	04/21/2014
ORBACTIV (IR 1204701)	Egypt	1204701	04/21/2014	1204701	04/21/2014
ORBACTIV (IR 1204701)	European Union (Community)	1204701	04/21/2014	1204701	04/06/2015
ORBACTIV (IR 1204701)	India	2721870	04/21/2014	1631882	08/23/2017
ORBACTIV (IR 1204701)	Int'l Registration-Madrid Agreement/Protocol	1204701	04/21/2014	1204701	04/21/2014
ORBACTIV (IR 1204701)	Japan	1204701	04/21/2014	N/A	N/A
ORBACTIV (IR 1204701)	Kazakhstan	1204701	04/21/2014	1204701	04/21/2014
ORBACTIV (IR 1204701)	Republic of Korea	1204701	04/21/2014	N/A	N/A
ORBACTIV (IR 1204701)	Mexico	M1494890	04/21/2014	1517985	2/26/2015
ORBACTIV (IR 1204701)	New Zealand	1204701	04/21/2014	1204701	11/15/2013
ORBACTIV (IR 1204701)	Norway	201406384	06/05/2014	1204701	04/21/2014
ORBACTIV (IR 1204701)	Russian Federation	1204701	04/21/2014	1204701	04/21/2014
ORBACTIV (IR 1204701)	Singapore	T1408816C	04/21/2014	1204701	02/13/2015
ORBACTIV (IR 1204701)	Switzerland	1204701	04/21/2014	1204701	04/21/2014
ORBACTIV (IR 1204701)	Turkey	1204701	04/21/2014	201455248	02/23/2015
ORBACTIV (IR 1204701)	Ukraine	1204701	04/21/2014	1204701	04/21/2014

<u>Trademark</u>	<u>Country</u>	<u>Application #</u>	<u>Application Date</u>	<u>Registration #</u>	<u>Registration Date</u>
ORBACTIV (IR 1204701)	Vietnam	1204701	04/21/2014	1204701	04/21/2014
 <b>Orbactiv</b> (oritavancin)  (IR 1444014)	Brazil	916302342	11/23/2018	916302342	08/27/2019
 <b>Orbactiv</b> (oritavancin)  (IR 1444014)	Canada	1932002	11/22/2018	N/A	N/A
 <b>Orbactiv</b> (oritavancin)  (IR 1444014)	Australia	1444014	11/21/2018	1982519	7/29/2019
 <b>Orbactiv</b> (oritavancin)  (IR 1444014)	China (People's Republic)	1444014	11/28/2018	1444014	03/25/2019
 <b>Orbactiv</b> (oritavancin)  (IR 1444014)	Egypt	1444014	11/21/2018	1444014	11/21/2018
 <b>Orbactiv</b> (oritavancin)  (IR 1444014)	European Union (Community)	1444014	11/21/2018	1444014	06/11/2019
 <b>Orbactiv</b> (oritavancin)  (IR 1444014)	Int'l Registration-Madrid Agreement/Protocol	1444014	11/21/2018	1444014	11/21/2018

<u>Trademark</u>	<u>Country</u>	<u>Application #</u>	<u>Application Date</u>	<u>Registration #</u>	<u>Registration Date</u>
 <b>Orbactiv</b> (oritavancin) (IR 1444014)	Japan	2019350704	11/21/2018	1444014	11/21/2018
 <b>Orbactiv</b> (oritavancin) (IR 1444014)	Republic of Korea	1444014	11/21/2018	1444014	
 <b>Orbactiv</b> (oritavancin) (IR 1444014)	Mexico	M2157203	11/21/2018	2014909	6/26/2019
 <b>Orbactiv</b> (oritavancin) (IR 1444014)	New Zealand	1444014	11/21/2018	1444014	05/23/2019
 <b>Orbactiv</b> (oritavancin) (IR 1444014)	Norway	201900430	01/10/2019	1444014	11/21/2018
 <b>Orbactiv</b> (oritavancin) (IR 1444014)	Singapore	40201900864W	11/21/2018	1444014	11/21/2018
 <b>Orbactiv</b> (oritavancin) (IR 1444014)	Switzerland	1444014	11/21/2018	1444014	11/21/2018
 <b>Orbactiv</b> (oritavancin) (IR 1444014)	Turkey	201960933	11/21/2018	N/A	N/A

<u>Trademark</u>	<u>Country</u>	<u>Application #</u>	<u>Application Date</u>	<u>Registration #</u>	<u>Registration Date</u>
 <b>Orbactiv</b> (oritavancin) (IR 1444014)	Ukraine	1444014	11/21/2018	1444014	11/21/2018
 <b>Orbactiv</b> (oritavancin) (IR 1444014)	Vietnam	1444014	11/21/2018	1444014	11/21/2018

ny-2005749